Effects of Trimetazidine Pretreatment on Endothelial Dysfunction and Myocardial Injury in Unstable Angina Patients Undergoing Percutaneous Coronary Intervention
Table 1
Baseline characteristics of the control and trimetazidine groups.
Characteristics
Control group
Trimetazidine group
values
Cases (n)
49
48
Age (years)
64.22 ± 10.54
65.59 ± 12.07
0.399
Gender (male/female)
31/18
27/21
0.766
Hypertension (yes/no)
30/19
30/18
0.412
Diabetes (yes/no)
11/38
8/40
0.195
Cerebral infarction (yes/no)
4/45
8/40
0.240
Atrial fibrillation (yes/no)
2/47
1/47
0.845
Smoking (yes/no)
36/13
31/17
0.353
TC (mmol/L)
5.09 ± 1.08
4.86 ± 1.07
0.525
TG (mmol/L)
2.26 ± 1.92
1.78 ± 1.01
0.208
LDL-C (mmol/L)
2.94 ± 0.89
2.78 ± 0.64
0.627
HDL-C (mmol/L)
1.21 ± 0.38
1.12 ± 0.23
0.294
LVEF
0.56 ± 6.32
0.55 ± 7.83
0.822
Arterial stenosis (n)
2.26 ± 0.81
2.46 ± 0.73
0.389
Stent (n)
1.54 ± 0.74
1.68 ± 0.82
0.130
Blood collection time after PCI (h)
16.70 ± 2.46
16.68 ± 3.42
0.543
TC, total cholesterol; TG, triglyceride; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; LVEF, left ventricular ejection fraction.
